Back to Browse Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 4

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity

Authors Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, et al

Published Date November 2009 Volume 2009:4 Pages 421—430

DOI http://dx.doi.org/10.2147/COPD.S6300

Published 17 November 2009

Jon O Ebbert, Kirk D Wyatt, Ali Zirakzadeh, Michael V Burke, JT Hays

Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA

Abstract: Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Keywords: smoking cessation, chronic obstructive pulmonary disease, varenicline

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Varenicline for smoking cessation: efficacy, safety, and treatment recommendations

Jon O Ebbert, Kirk D Wyatt, J Taylor Hays, et al

Patient Preference and Adherence 2010, 4:355-362

Published Date: 13 September 2010

Readers of this article also read:

Colorimetric biosensing of targeted gene sequence using dual nanoparticle platforms

Thavanathan J, Huang NM, Thong KL

International Journal of Nanomedicine 2015, 10:2711-2722

Published Date: 2 April 2015

Development of an oral push–pull osmotic pump of fenofibrate-loaded mesoporous silica nanoparticles

Zhao Z, Wu C, Zhao Y, Hao Y, Liu Y, Zhao W

International Journal of Nanomedicine 2015, 10:1691-1701

Published Date: 3 March 2015

Nanomedicine strategies for treatment of secondary spinal cord injury

White-Schenk D, Shi R, Leary JF

International Journal of Nanomedicine 2015, 10:923-938

Published Date: 29 January 2015

Lower irritation microemulsion-based rotigotine gel: formulation optimization and in vitro and in vivo studies

Wang Z, Mu HJ, Zhang XM, Ma PK, Lian SN, Zhang FP, Chu SY, Zhang WW, Wang AP, Wang WY, Sun KX

International Journal of Nanomedicine 2015, 10:633-644

Published Date: 14 January 2015

Photothermal cancer therapy using graphitic carbon–coated magnetic particles prepared by one-pot synthesis

Lee HJ, Sanetuntikul J, Choi ES, Lee BR, Kim JH, Kim E, Shanmugam S

International Journal of Nanomedicine 2015, 10:271-282

Published Date: 30 December 2014

Correcting magnesium deficiencies may prolong life

Rowe WJ

Clinical Interventions in Aging 2012, 7:51-54

Published Date: 16 February 2012